The aim of this study was to describe and evaluate the initial use of allow molecular weight Heparin at a general hospital. We identified all the patients, who received Enoxaparin for the first 3 months as of their admittance to the hospital. Amongst other aspects we collected information about the risk factors, indication, dosage, therapeutic failure or complications and plasma Xa antifactor activity. During the study period 156 patients were treated with Enoxaparin. The grounds for its use were prophylaxis of postoperative venous thromboembolism in 102 cases (65%) and non-surgery-related venous thromboembolism in 54 (35%). The mean number (SD) of risk factors of venous thromboembolism per patient was 3.44 (1.31). The rate of exposure to Enoxaparin of the hospitalized population was 4.1%, although there was considerable variability between services (interval: 0-56%). The dose regimen was 20 mg administered subcutaneously every 24 hours in 99% of the cases. We used other preventive measures simultaneously in 2 patients (1%). Of the 102 surgical patients 30 (31%) received a preoperative dose; its administration was not connected with the mean number of postoperative venous thrombosis risk factors. The mean Xa antifactor activity (SD) was 0.32 (0.1) IU/ml; in 77% of the determinations it was between 0.1 and 0.4 IU/ml. The initial use of Enoxaparin at a general hospital complied with recommended doses and schedules, although we did not abide very closely by the recommendation to administer a preoperative dose to patients subjected to surgery.
|Translated title of the contribution||Introduction and initial use of Enoxaparin at a general hospital|
|Number of pages||7|
|Publication status||Published - 1993|